{"entity":{"id":"freenome","kind":"company","name":"Freenome","aka":[],"tldr":"Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.","summary":"FDA approved SimpleScreen CRC on 24 July 2026 for average-risk adults 45+ based on PREEMPT CRC (>48,000 participants; ~80% CRC sensitivity, ~90% specificity). Freenome listed via a $330M SPAC merger (2025-26); Abbott holds US commercial rights and paid a $100M approval milestone; launch expected autumn 2026.","asOf":"2026-09-04","links":[{"label":"FDA approval (MedTech Dive)","url":"https://www.medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290/"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["early-detection"],"technologies":["mced","liquid-biopsy","methylation-profiling"],"targets":[],"drugs":["shield"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.freenome.com","ticker":"FRNM","investors":[],"funding":[]},"route":"/companies/freenome/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/"},{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/"}],"bottleneck":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"idea":[{"id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"company":[{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/"},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/"},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/"}],"trial":[{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/"}],"paper":[{"id":"paper-preempt-crc-shaukat-jama-2025","kind":"paper","name":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","route":"/key-papers/paper-preempt-crc-shaukat-jama-2025/"}]}}